KR101823997B1 - Beverage comprising extract of Korean Maca for improving erectile dysfunction - Google Patents
Beverage comprising extract of Korean Maca for improving erectile dysfunction Download PDFInfo
- Publication number
- KR101823997B1 KR101823997B1 KR1020150189597A KR20150189597A KR101823997B1 KR 101823997 B1 KR101823997 B1 KR 101823997B1 KR 1020150189597 A KR1020150189597 A KR 1020150189597A KR 20150189597 A KR20150189597 A KR 20150189597A KR 101823997 B1 KR101823997 B1 KR 101823997B1
- Authority
- KR
- South Korea
- Prior art keywords
- maca
- extract
- present
- erectile dysfunction
- korean
- Prior art date
Links
- 235000000421 Lepidium meyenii Nutrition 0.000 title claims abstract description 65
- 240000000759 Lepidium meyenii Species 0.000 title claims abstract description 65
- 235000012902 lepidium meyenii Nutrition 0.000 title claims abstract description 65
- 208000010228 Erectile Dysfunction Diseases 0.000 title abstract description 23
- 201000001881 impotence Diseases 0.000 title abstract description 23
- 235000013361 beverage Nutrition 0.000 title abstract description 8
- 239000000284 extract Substances 0.000 title description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 229940010454 licorice Drugs 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- 230000036299 sexual function Effects 0.000 description 14
- 238000010171 animal model Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000005226 corpus cavernosum Anatomy 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000001550 testis Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000001856 erectile effect Effects 0.000 description 6
- 238000002481 ethanol extraction Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000001625 seminal vesicle Anatomy 0.000 description 5
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 5
- 201000010653 vesiculitis Diseases 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940124549 vasodilator Drugs 0.000 description 4
- 239000003071 vasodilator agent Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 108010078321 Guanylate Cyclase Proteins 0.000 description 3
- 102000014469 Guanylate cyclase Human genes 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 3
- 230000009986 erectile function Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940083618 sodium nitroprusside Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 101150098694 PDE5A gene Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000018052 penile erection Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000438 udenafil Drugs 0.000 description 1
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a beverage composition for improving erectile dysfunction comprising domestic maca and a process for producing the same.
Description
The present invention relates to a food and health functional food field, and more particularly, to a composition for improving erectile dysfunction including domestic maca and a process for producing the same.
Erectile dysfunction refers to the case where the male erectile function is not sufficient for sexual activity or the erectile state can not be maintained even if the erect state is present. Erectile dysfunction refers to the case where sexual dysfunction occurs in about 25% of the total sex. The causes of erectile dysfunction can be classified into psychogenic and mental problems caused by mental or physical problems. In particular, about 50% or more of total erectile dysfunction is mature, and the proportion of maternal is further increased with age. Psychological factors include anxiety for failure, guilt, fear, depression, mental conflict with women, lack of physical attractiveness of women, and worry about aging. Substantial erectile dysfunction includes neurotic, endocrine, vascular, Neurogenic erectile dysfunction is caused by brain tumor, spinal cord injury, peripheral neuropathy caused by diabetes or chronic alcoholism. The penile erection phenomenon is caused by the relaxation of the vascular smooth muscle of the cavernous cavernosum and the increase of the blood flow. When the sexual reaction occurs, relaxation reaction occurs by the endothelial relaxation factor, nitric oxide (NO) secreted from the vascular endothelial cells.
NO is a potent neurotransmitter of nonadenergic noncholinergic (NANC) neurons in the central and peripheral nervous system and is biosynthesized by nitric oxide synthase (NOS). NO promotes the biosynthesis of cyclic-GMP (c-GMP) through activation of guanylate cyclase in the corpus cavernosum, and therefore, expansion of vascular smooth muscle through c-GMP and increase of intracerebral blood inflow enable erection (8). In addition, c-GMP is degraded by phosphodiesterase (PDE), and the activity of PDE is inhibited in order to maintain paw function (9,10). Recently, sildenafil (Viagra, Pfizer), a PDE5 (phosphodiesterase type V) inhibitor, has been approved by the FDA as an effective oral treatment for erectile dysfunction, and has been widely prescribed in Korea due to the development of Zydena in Dong- . Sildenafil inhibits cGMP degradation by inhibiting PDE5 and induces penile erection under sexual excitement. Except for the fact that it is a temporary drug only for sexual intercourse and has few complications such as blood pressure and death, and is positive for improving erectile function, erectile dysfunction is essential And the use of the drug as a medicament to be treated is difficult. Therefore, many research capabilities are being applied to natural products or herbal medicines that can treat erectile dysfunction while minimizing human side effects through the current administration.
Maca, which is used not only as food but also as a traditional medicine, is known to be very effective in enhancing sexual function among both Indians in the Andean region, and has been proven through animal experiments and clinical trials. Zheng et al. (14) reported that when maca extracts were consumed in rats with testicles removed, the time to erection was significantly reduced as well as the erectile function. Cicero et al. . In addition, Gonzales et al., In healthy adult men aged 21-56, consumed 1.5 g and 3.0 g of maca a day for about 12 weeks, and after 8 weeks of intake, the maca intake group was significantly . However, there was no correlation between male sex hormone and sex hormone. However, the effect on the sexual function improvement of maca known to date is mostly in the peracid, and research on domestic maca has not been reported yet. Korean Patent Publication No. 10-2011-0017478 discloses a microbial fermentation composition for tanning using maca, And the constitution thereof is different from that of the present invention as an invention relating to the production method.
SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide a composition for improving sexual function comprising maca and bokbunja.
In addition, it is an object of the present invention to provide a method for producing a composition for improving sexual function comprising maca and brambles.
In order to solve the first technical problem described above, the present invention provides a composition for improving sexual function comprising maca.
According to one embodiment of the present invention, there can be provided a composition for improving sexual function comprising an extract obtained by extracting maca or a fraction thereof as an active ingredient.
According to another embodiment of the present invention, the extraction may be hot water extraction or ethanol extraction.
According to another embodiment of the present invention, the extraction may be performed using 900-1000 parts by weight of solvent relative to 100 parts by weight of maca.
According to another embodiment of the present invention, the hot water extraction may be performed under a temperature condition of 60 ° C to 100 ° C.
According to another embodiment of the present invention, the ethanol extraction may be performed under a temperature of 75 ° C to 85 ° C.
According to another embodiment of the present invention, ethanol and distilled water of the ethanol extraction may be mixed and extracted at a volume ratio of 45:55 to 55:45.
According to another embodiment of the present invention, there can be provided a beverage composition for sexual function improvement comprising the maca or the extract or the fraction.
According to another aspect of the present invention, there is provided an extracting step of extracting maca and preparing an extract to solve the second technical problem. Mixing the extract solution with a sub ingredient and mixing the mixture; And a packaging step of filtering and packaging the mixed solution.
According to another embodiment of the present invention, the ingredient may include one or more selected from the group consisting of licorice concentrate, vitamin C, oligosaccharide, brambly or purified water.
The composition for improving sexual function comprising maca according to the present invention has the effect of providing a safe food and health functional food composition which prevents and improves the problem of lowering of sexual function, which is frequently occurring in modern people.
1 is a flow chart conceptually showing a method of manufacturing a maca composition according to an embodiment of the present invention.
FIG. 2 is a graph showing the effect of maca extract according to another embodiment of the present invention on the production of NO (nitric oxide), a vasodilator.
FIG. 3 is a graph showing the effect of maca extract according to another embodiment of the present invention on the number of spermatozoa.
FIG. 4 is a graph showing the results of analysis of NO content in the corpus cavernosum according to another embodiment of the present invention. FIG.
5 is a graph showing the effect of maca according to another embodiment of the present invention on GOT and GPT concentrations in serum of experimental animals.
Hereinafter, the present invention will be described in detail.
It is noted that the technical terms used in the present invention are used only to describe specific embodiments and are not intended to limit the present invention. In addition, the technical terms used in the present invention should be construed in a sense generally understood by a person having ordinary skill in the art to which the present invention belongs, unless otherwise defined in the present invention, Should not be construed to mean, or be interpreted in an excessively reduced sense. In addition, when a technical term used in the present invention is an erroneous technical term that does not accurately express the concept of the present invention, it should be understood that technical terms that can be understood by a person skilled in the art are replaced with a technical term. And should not be construed as being excessively reduced in meaning, and the singular expressions used in the present invention include plural expressions unless the context clearly dictates otherwise. ≪ RTI ID = 0.0 > And it is to be understood that the present invention may be embodied with additional constituent elements or steps. In the following description of the present invention, a detailed description of related arts will be omitted. It is omitted.
In order to solve the first technical problem described above, the present invention provides a composition for improving sexual function comprising maca.
According to one embodiment of the present invention, there can be provided a composition for improving sexual function comprising an extract obtained by extracting maca or a fraction thereof as an active ingredient.
According to another embodiment of the present invention, the extraction may be hot water extraction or ethanol extraction.
According to another embodiment of the present invention, the extraction may be performed using 900-1000 parts by weight of solvent relative to 100 parts by weight of maca.
According to another embodiment of the present invention, the hot water extraction may be performed under a temperature condition of 60 ° C to 100 ° C.
According to another embodiment of the present invention, the ethanol extraction may be performed under a temperature of 75 ° C to 85 ° C.
According to another embodiment of the present invention, ethanol and distilled water of the ethanol extraction may be mixed and extracted at a volume ratio of 45:55 to 55:45.
According to another embodiment of the present invention, there can be provided a beverage composition for sexual function improvement comprising the maca or the extract or the fraction.
According to another aspect of the present invention, there is provided an extracting step of extracting maca and preparing an extract to solve the second technical problem. Mixing the extract solution with a sub ingredient and mixing the mixture; And a packaging step of filtering and packaging the mixed solution.
According to another embodiment of the present invention, the ingredient may include one or more selected from the group consisting of licorice concentrate, vitamin C, oligosaccharide, brambly or purified water.
Hereinafter, the constitution and effects of the present invention will be described in more detail with reference to the following Production Examples, Examples, Comparative Examples and Experimental Examples. These embodiments are only for illustrating the present invention, and the scope of the present invention is not limited by these embodiments.
≪ Preparation Example > Preparation of maca extract
Maca was produced and tested with 9 kinds of extracts, which are different from solvent and extraction temperature, using 3 kinds of Peru and domestic. (Water, 50% ethanol) of 10 times the weight of maca was added, and the mixture was heated and extracted twice at 80 ° C with water extraction at 60 ° C and 100 ° C using a reflux condenser for 2 hours. The extracts were filtered, concentrated and lyophilized (PETED10R, Ilsinbiobase, Dongducheon, Korea). The extraction conditions are shown in Table 1 below.
The imported maca (premium) and imported maca (normal type) in Table 1 are Peru acid, DW means purified water, and 50% EtOH means ethanol mixed with ethanol and distilled water at a volume ratio of 50:50.
≪ Experimental Example 1 > Cell line and cell culture
HUVEC, a human umbilical vein epithelial cell line, was used to investigate the effect of maca extract on NO (vasodilator) production. The HUVAC cell line was purchased from the Korean Cell Line Bank, and 10% fetal bovine serum (PAA, Etobicoke, ON, canada) which was heat-treated at 56 ° C for 30 min and antibiotics (penicilin / streptomycin, Lonza, Walkersville , MD, USA) was added and incubated at 37 ° C in a humidified 90%, 5% CO 2 incubator.
<Experimental Example 2> Measurement of NO (notric oxide) concentration
Using 9 kinds of maca extracts listed in Table 1, the effect on the production of NO as a blood vessel relaxation factor was examined. HUVEC cells were diluted at a concentration of 1 × 10 5 cells / mL in a 12-well culture dish and dispensed. After 24 hours, the extract was treated with 200 ug / ml of the extract and sodium nitroprusside (SNP) as a positive control. Cell culture was obtained 24 hours after the treatment. The cell culture of the treated group was centrifuged to obtain supernatant. Then, the supernatant was mixed with 150 μl of the supernatant, 20 μl of the griess reagent reagent, and 130 μl of H 2 O, and the mixture was reacted at room temperature for 30 minutes. The absorbance of the reaction was then measured at 548 nm using a microplate reader (Bio-Tek).
Experimental Example 3 Breeding and Diet of Experimental Animals
In the experimental group, Sprague Dawley male rats (KOSA BIO), which was 7 weeks old, were adapted to general diet for 1 week. Then, total weight of rats was divided into 5 groups of 9 rats per liver Respectively. The temperature of the laboratory animal room was maintained at 22 ± 2 ℃ and the relative humidity was maintained at 50 ± 5%. The darkness was controlled to 12 hours (7:00 19:00). The animal test was conducted with the permission of the Animal Experimental Ethics Committee (BBRI-IACUC-15003) of the Center for Efficacy Assessment of the Barry & Bio Foods Research Institute.
The classification of the experimental group, the substance to be administered and the dose are shown in Table 2 below. In the control and experimental groups, erectile dysfunction was induced by chronic alcohol intoxication with daily oral administration of 20% EtoH. In the experimental group, 250, 500, and 1000 mg / kg of maca extract per body weight were administered once a day for 30 days Orally. The control group received the same amount of water. Diets were chow diet, filtered and sterilized with ultraviolet sterilizer. Body weight was measured once a week, and dietary and intakes were measured weekly at the same time.
<Experimental Example 4> Blood collection and tissue collection
Sacrifice was carried out after fasting for 12 hours. Anesthetized with diethyl ether, blood was drawn through the abdominal vein immediately after opening. The blood in the EDTA tube was centrifuged at 2,000 g for 10 minutes and the supernatant was separated. The serum was separated and analyzed by GOT and GPT. The testis, seminal vesicles and penile corpuscles were separated and weighed, and the tissues were stored frozen at 80 ° C for analysis.
<Experimental Example 5> Measurement of sperm count in testis
After the incision of the abdomen of the rats, both testes were weighed and the tunica albuginea was removed. The testis was then incubated with 20 ml of physiological saline solution at 37 ° C for 20 minutes in a 50 ml test tube, and incubated with a hematocytometer .
<Experimental Example 6> Separation of corpus cavernosum and NO (nitric oxide) analysis in cavernosal bodies
Rat was sacrificed by ether and the lower abdomen was incised, and the penis tissue was removed to the site where it was branched down to the pubic bone. The penile corpuscles were separated from the extracted penis tissue, cleaned with physiological saline, and the remaining foreign substances and blood were removed with a filter paper. After the homogenization of the corpus cavernosum, an enzyme source was obtained and used for NO determination. The procedure for obtaining the enzyme source was carried out using the Nitric Oxide Assay Kit (ab65328, abcam, Cambridge, UK).
<Experimental Example 7> Analysis of serum testosterone
Serum was used to determine testosterone content in serum using the Testosterone ELISA kit (ab108666, abcam).
The statistical analysis of Experimental Examples 1 to 7 is shown by the mean ± standard deviation of the experimental results. Stdent's t- test method was used for statistical analysis between the two groups. P <0.05 was considered statistically significant
(1) NO concentration change in HUVEC cells
2 is a graph showing the effect of maca extract on the production of nitric oxide (NO), a vasodilator.
2, 9 kinds of maca extracts were used to investigate the effect of maca on the production of NO, a vasodilator. The positive control group, SNP, is separated into cyanide and NO through interaction with oxyhemoglobin. It is known that isolated NO stimulates guanylate cyclase (GC) of smooth muscle to increase the production of cGMP, resulting in vasorelaxation. In the above experiment, NO was increased 2.2 or 8.9 times at 20 and 100 uM, respectively. In the case of maca extract, it was 2.3 times higher than that of 20 uM in the positive control group. Based on this, a sample of
(2) Weight gain, negative intake and dietary intake
In SD rats, erectile dysfunction was induced by 20% ethanol, and the extracts of maca were orally administered at 250, 500, and 1000 mg / kg. The body weight gain, the amount of water intake, and the amount of dietary intake of the test animals were as shown in Table 3 below. Weight gain tended to decrease in the erectile dysfunctional animal model compared to the normal control group, but did not change significantly in the maca-treated group, but the maca extract was administered at a dose of 500 or 1000 mg / Significant changes were investigated. Negative intake was significantly reduced in the erectile dysfunctional animal model compared to the normal control group, but there was no significant decrease in dietary intake. On the other hand, administration of
(3) Reproductive organ and number of spermatids in maca
Table 4 shows the results of comparing the weights of erectile dysfunctional testes and seminal vesicles with erectile dysfunction model after oral administration of distilled water or macaques for 4 weeks. The weight of testis and seminal vesicle decreased numerically by ethanol administration, but statistically similar to the control group.
3 is a graph showing the effect of maca extract on the number of spermatozoa. As shown in FIG. 3, the number of spermatozoa in the erectile dysfunction model group was decreased in comparison with that in the normal group, and in the group treated with the maca extract, the concentration of the erectile dysfunction model was significantly increased from 2 to 3.3 times. Gonzales et al. Reported that weight loss and reduced sperm counts induced in high altitude regions were suppressed in maca-fed rats. In addition, rats that had decreased sperm counts by treatment with insecticides such as malicion and acaricide also showed improvement in sperm count Has been proven. Therefore, it can be said that the production of sperm which was inhibited by ethanol administration can significantly increase the production of sperm by the administration of maca.
(4) Effect of maca on NO production in penile corpus cavernosum of experimental animals
4 is a graph showing the results of analysis of NO content in the corpus cavernosum. As shown in FIG. 4, ethanol-administered erectile dysfunctional animal model group was reduced by about 23.7% compared with the normal group. On the other hand, the concentration of NO in the group treated with erectile dysfunction induction was increased in a concentration - dependent manner. Especially, the increase of NO content was observed at 1.4 and 1.3 times, respectively, in
(5) Effect of maca on GOT and GPT concentrations in serum of experimental animals
5 is a graph showing the effect of maca on GOT and GPT concentrations in serum of experimental animals. Referring to FIG. 5, GOT and GPT are damaged by hepatic enzymes, resulting in destruction of hepatocytes and release of blood, which is higher than normal values. In other words, GOT and GPT measurements can be used to indirectly determine whether liver damage has occurred. GOT / GPT levels were increased in the erectile dysfunction model group but not in the normal control group and the erectile dysfunction model group. In the 250 mg / kg group, there was no improvement in liver damage, but in the 500 and 1000 mg / kg groups, GOT / GPT decreased and was effective in improving liver damage.
The nine types of Maca extract examined the effects on NO production of vasodilatory factors in HUVEC result, stylized most significantly increase NO production in domestic marker water extract group along the domestic marker water extract on the basis of in vitro experiments in vivo experiments. In the SD rats, erectile dysfunction was induced by 20% ethanol, and the domestic
Based on the results of the above studies, the following Production Examples were prepared. The% of the following preparations is v / v%.
The pouch-type beverage can be prepared by mixing 2 to 5% of maca extract, 1 to 3% of licorice concentrate, 0.1 to 3% of vitamin C and the remaining purified water. The pouch-type beverage can be prepared by adding 1 to 2% of maca extract, 0.1 to 3% of C, 4 to 5% of bokbun, and purified water of the rest are mixed and mixed into a glass bottle to prepare a glass bottle drink.
Table 5 below shows the mixing ratios of preparation examples of pouch-type maca beverages and glass bottle type maca beverages. The pouch type is prepared once per day, and the glass bottle type is prepared twice per day.
The composition for improving sexual function comprising maca according to the present invention has the effect of providing a safe food and health functional food composition which prevents and improves the problem of lowering of sexual function, which is frequently occurring in modern people.
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150189597A KR101823997B1 (en) | 2015-12-30 | 2015-12-30 | Beverage comprising extract of Korean Maca for improving erectile dysfunction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150189597A KR101823997B1 (en) | 2015-12-30 | 2015-12-30 | Beverage comprising extract of Korean Maca for improving erectile dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170079240A KR20170079240A (en) | 2017-07-10 |
| KR101823997B1 true KR101823997B1 (en) | 2018-02-01 |
Family
ID=59355285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150189597A KR101823997B1 (en) | 2015-12-30 | 2015-12-30 | Beverage comprising extract of Korean Maca for improving erectile dysfunction |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101823997B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240012913A (en) | 2022-07-21 | 2024-01-30 | 조용기 | Extraction method of maca and food composition including maca extract |
-
2015
- 2015-12-30 KR KR1020150189597A patent/KR101823997B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170079240A (en) | 2017-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102802636B (en) | Crocin hydrolysate | |
| Chuah et al. | In vitro and in vivo toxicity of garcinia or hydroxycitric acid: a review | |
| JP7429927B2 (en) | Sperm fertility enhancer | |
| CN101518336A (en) | Nutrition food with oxidation resistance function and preparation method thereof | |
| AU2018203677A1 (en) | Modified polyphenol compositions | |
| KR101312491B1 (en) | Manufacturing method of functional Momordica charantia beverage for lowering blood glucose | |
| KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
| US20160067270A1 (en) | Use of ginsenoside f2 for prophylaxis and treatment of liver disease | |
| Alshafei et al. | Red beet Peel-loaded Liposome's impact on metabolic syndrome rats and its use as fortifier in yoghurt powder | |
| US11253563B2 (en) | Composition for use in the treatment and/or prevention of infertility | |
| Laela et al. | The effect of kefir-spirulina on glycemic status and antioxidant activity in hyperglycemia rats. | |
| KR20100129571A (en) | Functional composition for improvement of sex and food having the same | |
| KR101823997B1 (en) | Beverage comprising extract of Korean Maca for improving erectile dysfunction | |
| WO2016141774A1 (en) | Uses of jilin ginseng oligopeptide in preparing food product or healthcare food product for improving and enhancing sexual function | |
| CN107684556A (en) | Prevention of hcc or therapeutic composition comprising GF2 | |
| US20190160126A1 (en) | Compositions and methods for treating reproductive indicators symptomatic of male infertility | |
| Velazquez et al. | Alternative medicine and molecular mechanisms in chronic degenerative diseases | |
| KR101552821B1 (en) | Enzymatic hydrolized Formica truncicola extract powder having vasodilatation, sexual function improvement and anti-inflammatory effect | |
| AU2021104673A4 (en) | Poly herbal green tea supplement for improving implantation & fertility | |
| JP5706142B2 (en) | Blood glucose lowering agent, visceral fat accumulation inhibitor, TG lowering agent, faecal fat excretion promoter containing ethanol extract of Fuyubodaiju flower as an active ingredient | |
| US20230364069A1 (en) | Method for treating non-alcoholic steatohepatitis through co-administration of curcumin derivative and tgf-b receptor inhibitor | |
| Ivanova et al. | Food additives with beneficial effects in the treatment of erectile dysfunction, containing L-Arginine, Pycnogenol and Ginseng extract | |
| JP2011144147A (en) | Gaba-rich tomato-derived composition having anti-stress effect | |
| TWI745609B (en) | Composition for promoting antioxidative activity | |
| Martin et al. | The effects of a novel red spinach extract on graded exercise testing performance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |